How the New Five‑Day Limit Changes Your Use of Decongestant Nasal Sprays
The MHRA now caps over‑the‑counter nasal decongestants at five days. Learn why, the risks of longer use, and safer alternatives for winter congestion.
The new five‑day rule and why it matters
Winter brings colds, flu and dry air, so reaching for a nasal spray feels almost inevitable. According to Patient.info FeatureArticle, the Medicines and Healthcare products Regulatory Agency (MHRA) now advises that sprays containing xylometazoline or oxymetazoline should not be used for more than five consecutive days – a tightening from the previous seven‑day ceiling. The change matters because using these sprays beyond five days increases the chance of rebound congestion and, in rare cases, permanent damage to the nasal lining.
How decongestant sprays work
Decongestant sprays belong to a class of drugs called topical sympathomimetics. They stimulate alpha‑adrenergic receptors on the smooth muscle that surrounds the tiny blood vessels in the nasal mucosa. This causes the vessels to constrict, reducing the swelling that blocks airflow. The effect is rapid – most people feel relief within minutes – which explains why the sprays are popular for sudden blockage.
The vasoconstriction is reversible; once the drug wears off, the vessels dilate again. With repeated dosing, the lining can become less responsive, a phenomenon called tachyphylaxis. If the spray is stopped after the recommended period, the sudden loss of the constricting effect can lead to a surge of blood flow, swelling the tissue even more than before. This overshoot is what clinicians call rhinitis medicamentosa, or rebound congestion.
Risks of crossing the five‑day line
The source lists several complications that become more likely after five days of continuous use:
| Complication | Typical onset after start | Frequency (as reported) |
|---|---|---|
| Rebound congestion (rhinitis medicamentosa) | 5‑7 days | Common when use exceeds recommendation |
| Dry, raw nasal lining (burning, crusting) | 3‑5 days | Frequent |
| Nosebleeds | 4‑6 days | Occasional |
| Temporary loss of smell | 5‑7 days | Uncommon |
| Septal perforation (hole in the septum) | >10 days, prolonged misuse | Rare |
The most immediate concern is the self‑reinforcing cycle: as the spray’s effect fades, the nose feels more blocked, prompting another dose, which further desensitises the tissue. ENT surgeon Samit Unadkat stresses that this is not an addiction in the classic sense, but the psychological reliance on the bottle can be strong.
Beyond the discomfort, chronic rebound congestion can mask the underlying cause – whether a viral infection, allergic rhinitis or a structural issue such as a deviated septum. Continuing to spray delays proper assessment and treatment.
Safer alternatives for longer‑term relief
When the five‑day limit is reached, the evidence points to other strategies that carry far fewer risks.
- Saline nasal irrigation – isotonic salt water flushes excess mucus and keeps the mucosa moist without pharmacological action. It can be used several times a day throughout the illness.
- Intranasal steroid sprays – low‑dose corticosteroids such as fluticasone reduce inflammation over a few days and are safe for prolonged use under NHS guidance.
- Humidification – a cool‑mist humidifier restores ambient moisture, easing dryness that often worsens congestion.
- Targeted allergy treatment – antihistamine tablets or nasal antihistamine sprays address the allergic component directly.
- Non‑pharmacological measures – staying hydrated, elevating the head while sleeping, and gentle steam inhalation help thin mucus and improve drainage.
A simple comparison helps visualise the trade‑offs:
| Option | Time to noticeable relief | Typical duration of safe use | Main side‑effects |
|---|---|---|---|
| Decongestant spray (xylometazoline/oxymetazoline) | 5‑10 min | ≤5 days | Rebound congestion, dryness, rare septal perforation |
| Saline rinse | 10‑15 min | Unlimited | Rare stinging if solution is too concentrated |
| Intranasal steroid | 24‑48 h | Weeks to months (under doctor’s guidance) | Mild nasal irritation, rare nosebleeds |
| Humidifier | Variable (depends on room humidity) | Unlimited | Needs regular cleaning to avoid mould |
| Oral antihistamine | 30‑60 min | As directed (often 7‑14 days) | Drowsiness, dry mouth |
The table shows that while decongestant sprays win on speed, they carry the steepest risk curve after a short window. Saline and steroids are slower but safe for repeated use.
Who benefits and who may be disadvantaged
The new guidance primarily protects frequent users – people with recurrent colds, seasonal allergies or a habit of keeping a spray at the bedside. For them, the five‑day cap forces a switch to more sustainable options, potentially reducing chronic nasal irritation and the need for specialist referral.
Conversely, occasional users who follow the limit faithfully experience little change. The rule may feel restrictive to those who rely on a quick fix during a severe cold, but the evidence suggests the short‑term gain is outweighed by the risk of a longer‑lasting blockage.
Pharmacies and manufacturers could see a dip in sales of over‑the‑counter decongestants, while sales of saline kits and steroid sprays may rise. Healthcare providers may notice a modest increase in consultations for persistent congestion, but these visits allow a more accurate diagnosis of underlying issues.
What could go wrong or remains uncertain
The MHRA’s five‑day recommendation is based on pharmacovigilance data, yet the exact threshold where rebound congestion becomes likely varies between individuals. Factors such as age, nasal anatomy and the presence of underlying inflammation may shift the safe window.
The source does not quantify the proportion of users who develop septal perforation, only noting it as a rare outcome. Without robust incidence figures, clinicians must balance anecdotal warnings with the overall low probability.
Another gap is guidance on how to wean someone off a spray after five days. Some patients experience a sudden flare‑up when the spray stops, leading them to restart despite the warning. Evidence‑based tapering protocols are scarce, leaving clinicians to rely on trial‑and‑error.
Finally, the article mentions steroid nasal sprays as a “better long‑term option” but does not discuss potential systemic absorption or the need for prescription in the UK. Readers should be aware that while low‑dose steroids are generally safe, they still warrant professional oversight.
A practical step for this week
If you find yourself reaching for a decongestant spray, set a timer for five days. On day five, switch to a saline rinse and consider a humidifier for the night. Note any change in symptoms and, if congestion persists beyond a week, book an NHS appointment to explore whether allergies, a viral infection or a structural issue is the root cause.
